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Abstract 
Background: To estimate  plasma levels of natural 
anticoagulants, i.e., Protein C, Protein S and 
Antithrombin III in patients with solid malignancies 
Methods: A  cross-sectional study was conducted 
wherein plasma levels of Protein C,S and 
Antithrombin III (AT III)  in patients with solid 
malignancies were determined. The studied 
parameters included age, gender ,type of the tumor, 
stage of the cancer and  plasma levels of protein C, S 
and antithrombin.A total of 91 samples from patients 
with solid tumors were selected using consecutive 
non-probability sampling method..Protein C,S and 
antithrombin levels in the plasma were determined 
using fully automated coagulation analyzer CA-500 
(Sysmex Japan). 
Results:  Total 91 patients fulfilled the inclusion 
criteria. The age range was 30 to 70 years. Mean age 
was 47.87±13.56 years . Out of the 91 patients, 43 
(47.23%) were females and 48 (52.73%) were males, 
with a male to female ratio of1.1:1. Frequent 
malignancies noted in males were head and neck 
(10.98%), GIT (9 %), lymphoma (8.79%). In females 
breast cancer was the most common cancer 
accounting for 14.28 % followed by GIT (9.89 %), 
Head and neck (7.69 %) . Majority of the patients 
(67%) were in stage IV .Out of 91 patients, 58,2% and 
4.4% were found Protein S and C deficient, 
respectively. AT III levels were above normal in 
majority (53.8%).With regards to stage of tumor 
decreased levels of these natural anticoagulants  in 
stage I, II, III and IV were 2.19%, 3.29%, 6.59% and 
48.35% respectively . Higher incidence of 
thrombophilia was noted in patients with Ca breast 
(20%) followed by tumors of G.I.T and tumours of 
head and neck due to low levels of Protein S .  
Conclusion: Increased frequency of thrombophilia 
is noted in patients with solid tumors (60%).Protein 
S deficiency is a major factor (92.7% of the total 
thrombophilic patients) leading to thrombophilic 
state in cancer population. 
Key Words:  Thrombophilia ,Protein C, Protein S, 
Antithrombin, Solid tumors 
Introduction 
     Malignancy is a hypercoagulable state. Majority of 
patients with solid tumors and leukemias may have 
subclinical hypercoagulable state with abnormalities of 
coagulation profiles only.Clinically apparent 
thromboembolism presents as arterial and venous 
thrombosis, migratory thrombophlebitis, thrombotic 
non bacterial endocarditis, thrombotic 
microangiopathy and/or, disseminated intravascular 
coagulation.1 It has leading place among non cancer 
causes of death in patients with malignancy. Annual 
death rate for venous thromboembolism in population 
of cancer patients is 47 fold greater than the general 
population and the prevalence of unsuspected venous 
thrmboembolism is 6.3% in cancer patients.2,3 
     Pathogenesis of thrombosis in cancer is 
multifactorial.4 Deficiencies in Antithrombin III, 
protein C or protein S, the three core inhibitors of 
coagulation cascade, substantially increase the risk of 
venous thromboembolism.5-11 Clotting activation also  
plays a role in tumor progression.1,2 Incidence of 
thrombosis in malignancy is 15% but in certain tumors 
e.g pancreatic carcinoma it may be as high as 50%. 1 
     Thrombotic events can influence the morbidity and 
mortality of the underlying disease of the patient. 
Therefore, preventing these complications in cancer 
patients is a clinically relevant issue. The finding of a 
strong thrombophilia has several clinical consequences 
most important being the fact that it decreases the 
threshold to recommend prophylactic anticoagulation. 
Identification of several markers of acquired cancer 
related thrombophilia state is thus necessary to 
prevent thrombotic events by giving them long term or 
short term prophylactic anticoagulant therapy.  
 
Patients and Methods  
 A total of 91 patients of age range 30 – 70 years 
affected by gastrointestinal, breast, gynecological and 
lung cancer of various stages diagnosed on 
histopathology reports/computed tomography scan or 
magnetic resonance imaging were included in the 
study. Patients with known inherited thrombophilia 
(i.e. Protein C, S deficiency, AT III deficiency, activated 
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protein C resistance) were excluded on basis of  careful 
history taken and for any event of thrombosis in the 
past. Patients excluded from the study were female 
patients taking contraceptive pills, pregnant women., 
patients of inflammatory bowel disease, connective 
tissue disease, severe acute infectious disease, mental 
disorder, stroke or having neurosurgery within last six 
months. Also excluded  were patients taking 
anticoagulant treatment, diabetes mellitus, 
myeloproliferative disorders and paroxysmal 
nocturnal haemoglobinuria because of the possibility 
of concomitant haemostatic disorders, no episode of 
deep venous thrombosis and pulmonary embolism. 
   Venous blood samples were collected in vaccutainers 
containing 3.2 % sodium citrate as anti-coagulant in 
ratio of 9: 1.Samples  were centrifuged at 2000 g for 15 
minutes to separate platelet poor plasma i.e, platelet 
count  < 10,000/µL  platelets.Sera  were  aliquoted into 
labeled appondrof tubes and stored in freezer at -80° 
C. Protein C and antithrombin  was measured by 
using Berichrom Protein C reagents and antithrombin 
kit which gave determination of functionally active 
Protein C and antithrombin Dade  BehringProtein S Ac 
kit was used for estimation of free protein S. Analyses 
of Protein C,S and Antithrombin was done 
automatically in the Sysmex Coagulation analyser 500 
following manufacturer’s instruction manual. 
 
Results 
Total 91 patients fulfilled the inclusion criteria and 
enrolled in the study. The age range was 30 to 70 
years. Mean age was 47.87±13.56 years (Table 1). Out 
of the 91 patients, 43 (47.23%) were females and 48 
(52.73%) were males, with a male to female ratio 
of1.1:1. Frequent malignancies noted in males were 
head and neck (10.98%), GIT (9 %), lymphoma (8.79%). 
In females breast cancer was the most common cancer 
accounting for 14.28 % followed by GIT (9.89 %), and  
Head and neck (7.69 %) (Table 2). Majority of the 
patients  
Table 1: Age Distribution of patients  
Age (years) Male No(%) Female 
No(%) 
Total No(%) 
30-39  15 (16.48) 10(10.98) 25 (27.46) 
40-49 8(8.79) 15(16.48) 23(25.27) 
50-59 11(12.08) 11(12.08) 22 (24.16) 
60-70 14(15.38) 7 (7.60) 21(22.98) 
 
(67%) were in stage IV (Table 3)Out of 91 patients, 
58,2% and 4.4% were found Protein S and C deficient, 
respectively. AT III levels were above normal in 
majority (53.8%) (Figures 1-3).With regards to stage of 
tumor decreased levels of these natural anticoagulants 
 in stage I, II, III and IV were 2.19%, 3.29%, 6.59% and 
48.35% respectively (Table 4). Higher incidence of 
thrombophilia was noted in patients with Ca breast 
(20%) followed by tumors of G.I.T and tumours of 
head and neck due to low levels of Protein S (Table 5).  
Table 2:  Distribution of Different Malignant 
Neoplasms in males and females 
Tumor Type No (%) 
Male 
No(%) 
Female 
Gastrointestinal tumors 18(19.78) 9 (9.98) 9 (9.89) 
Tumors of female genital 
tract 
8(8.79) 0(0) 8 (8.79) 
Carcinoma breast 13(14.28) 0(0) 13(14.28) 
Tumors of head and neck 
region 
17(18.68) 10(10.98) 7 (7.69) 
Tumors of bone 4(4.39) 2(2.19) 2(2.19) 
Lymphoma 10(10.98) 8(8.79) 2(2.19) 
Respiratory system 4(4.39) 4(4.39) 0(0) 
Tumors of male genital tract 4(4.39) 4(4.39) 0(0) 
Brain tumor 6(6.59) 5(3.49) 1(1.09) 
Tumors of urinary tract 5(5.49) 4(4.39) 1(1.09) 
Skin &Integumentary 
system 
2(2.19) 2(2.19) 0(0) 
 91(100) 48(52.74) 43(47.25) 
 
Table 3: Stage of tumours 
Stage No(%) 
1 3  (3.3) 
2 12(13.2) 
3 15(16.5) 
4 61(67) 
 
Fig.1: Levels of Protein C in Different Solid Tumors 
 
Fig 2: Levels of Protein S in Different Solid Tumours 
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Fig.3:  Levels of ATIII in Different Solid Tumors 
 
Table 4:  Relationship of Thrombophilia with 
Stage of tumours 
 
 Thrombophilia 
Total no 
 of 
patients 
Normal 
Protein C 
deficiency 
Protein S 
deficincy 
Antithro
mbin 
deficien
cy 
 
Combined 
C & S 
deficiency 
 
Stage  of 
Tumor 
I 2 0 1 0 0 3 
II 10 0 2 0 0 12 
III 8 1 6 0 0 15 
IV 16 2 42 0 1 61 
Total no of 
patients 
36(40%) 3(3.3%) 51(56%) 0(0%) 1(1.2%) 91 
 
Table  5: Relationship of Thrombophilia with Type 
of tumour 
 
 Thrombophilia  
Normal 
Protein C 
deficiency 
Protein S 
deficiency 
Anti Thrombin 
deficiency 
Combined 
Deficiency 
% of the 
thrombophilic 
pts(n=55) 
Tumor 
Type 
Gastrointestinal 8 0 10 0 0 18.18% 
Female genital 
tract 
3 0 5 0 0 9.2% 
Breast Tumors 2 1 10 0 0 20% 
Head and neck 
region 
7 2 8 0 0 18.18% 
Tumors of bone 3 0 1 0 0 1.8% 
Lymphoma 3 0 6 0 1 12.72% 
Respiratory 
system 
2 0 2 0 0 3.63% 
Brain Tumor 2 0 4 0 0 7.27% 
Male genital 
tract 
1 0 3 0 0 5.5% 
Tumors of 
urinary tract 
3 0 2 0 0 3.63% 
Skin & 
Integumentary 
system 
2 0 0 0 0 0% 
Total no of patients 36 3 51 0 1  
 
Discussion 
      The world today is seeing a new epidemic of non-
communicable disease (NCD), cancer being one of 
them. It is the second leading cause of death in 
Pakistan. 12 Thromboembolism is the most frequent 
complication and the second cause of death in patients 
with overt malignant disease.13 A close interaction 
exists between cancer and venous thromboembolic 
disease. Cancer is an important risk factor for deep 
venous thrombosis (DVT).Its presence leads to a 6 fold 
increase in risk for venous thromboembolism.14 
Different tumors of different extent, with different 
comorbidities, may promote the development of 
thrombosis by different combinations of tumor and 
non – tumor associated pro-coagulant mechanisms. 
Thus all three mechanisms of Virchow’s are at play in 
patients with malignant disease i.e. stasis, activation of 
blood coagulation and vascular injury. Many of 
treatments are themselves thrombogenic; for example 
postoperative thromboembolism is a major risk after 
tumor excision or debulking. Some of the 
chemotherapeutic agents such as 
thalidomide/dexamethasone, tamoxifene and 
inhibitors of vascular endothelial growth factors 
(VEGF) are thrombogenic. 15 Clotting activation may 
play a role in tumor progression.1,2 Thromboembolic 
events lead to significant mortality and morbidity 
among patients of all ages. Studies show that annual 
death rate for venous thromboembolism in population 
of cancer patients is 47 fold greater than the general 
population. The prevalence of unsuspected venous 
thrombo-embolism is 6.3% in cancer patients.2,3 
Incidence of thrombosis in malignancy is 15% but in 
certain tumors e.g pancreatic carcinoma it may be as 
high as 50%.1 Therefore, to prevent these 
complications in cancer patients is a clinically relevant 
issue. It is frequently recognized that the majority of 
cancer patients present with one or more abnormalities 
of laboratory coagulation tests. Deficiencies in protein 
C, protein S and Antithrombin, the three core 
inhibitors of coagulation pathway, significantly 
increase the risk of venous thromboembolism. 5,6  
Deficiencies of these coagulation inhibitors in different 
malignancies is well documented. 7-11  
    According to the tumour registry data of Armed 
Forces Institute of Pathology AFIP , Rawalpindi (1992-
2001), Shaukat Khanum Cancer Institute, Lahore and 
international data, males outnumber females in 
frequency of malignant  tumours.This higher incidence 
may be due to differences in carcinogenic exposures, 
metabolic differences or susceptibility differences. 
Increased rates of smoking among men, differences in 
infections, hormones and contact with toxic metals 
may all come into play along with some reasons which 
are not fully understood. Also cancers related to work 
exposures are more common among men. If we can 
identify modifiable causes of sex difference in cancer 
incidence and mortality then preventative actions 
could reduce the cancer burden in both men and 
women. 12,16,18 
     As the tumour advances in stage there is greater 
risk of thrombophilia due to deficiency of Protein S 
and C. This association of thrombophilia with 
advanced stage of tumor may be explained by stasis 
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resulting from patient’s immobility, increased release 
of tumor associated procoagulants and cytokines, the 
reduction of naturally occurring inhibitors (eg. ATIII, 
protein C and protein S) due to metastasis and 
vascular injury due prolonged use of central venous 
catheters and endothelial damage secondary to 
chemotherapy. Also as already mentioned, clotting 
activation also plays a role in tumor progression hence 
increased frequency of protein S deficiency in stage IV 
tumor (i.e most advanced stage) in present study.1,2  
    This thrombophilic tendency can partially be 
ascribed to chemotherapy used in treatment. Studies 
show tamoxifen and cytotoxic therapy to 
independently increase risk of thrombosis.19 
Controlled studies have also shown that conventional 
chemotherapy routinely used in treatment of breast 
cancer increased risk of thromboembolism due to 
deficiencies of Protein C and Protein S.20 
     In present study most of the thrombophilic patients 
had Protein S deficiency (92.7% of the total 
thrombophilic patients). Cytokines released by 
malignant cells causes increase in Protein S binding 
protein resulting in decreased free Protein S. 
Anticancer chemotherapy may affect liver function 
and decrease the synthesis of both procoagulation and 
anticoagulation factors. 21 Increased plasma levels of 
antithrombin may be due to its antiproliferative, and 
anti angiogenic properties. Stratification of major 
thrombophilic factors according to their risk of 
thrombosis is based on the most thrombogenic factors 
such as deficiencies of natural coagulation inhibitors 
eg antithrombin deficiency, protein C deficiency, 
protein S deficiency. 22 
     As patients with cancer undergo a variety of 
procedures which may increase their risk of 
thrombosis e.g. exposure to hormonal and other 
therapies, extensive surgical procedures, and 
placement of indwelling catheters. Therefore, prior to 
initiating these interventions, one may consider testing 
the patient for the presence of factors which may 
predispose these patients to thrombophilia like 
deficiencies of protein C, S and Antithrombin. If 
thrombophilia is detected in a cancer patient one may 
consider avoiding central lines and starting the 
prophylactic anti coagulant therapy for example low 
molecular weight heparin, etc. 
Conclusion  
1.Increased frequency of thrombophilia is noted in 
patients with solid tumors( 60%) . 
2.Protein S deficiency is a major factor (92.7% of the 
total thrombophilic patients) leading to thrombophilic 
state in cancer population. 
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